scholarly journals Treatment of jejunal variceal bleeding with portal vein thrombosis after bile duct cancer surgery by short single‐balloon endoscope

2021 ◽  
Author(s):  
Yoshihiro Furuichi ◽  
Mitsuyoshi Honjo ◽  
Takao Itoi
Endoscopy ◽  
1995 ◽  
Vol 27 (08) ◽  
pp. 573-578 ◽  
Author(s):  
K. Tamada ◽  
K. Ido ◽  
N. Ueno ◽  
M. Ichiyama ◽  
T. Tomiyama ◽  
...  

2008 ◽  
Vol 6 (1) ◽  
Author(s):  
Mitsugi Shimoda ◽  
Yukihiro Iso ◽  
Shigeki Tomita ◽  
Takahiro Fujimori ◽  
Koji Murakami ◽  
...  

2018 ◽  
Vol 59 (1) ◽  
pp. 162
Author(s):  
Ja Kyung Yoon ◽  
Man-Deuk Kim ◽  
Do Yun Lee ◽  
Seok Joo Han

2021 ◽  
Vol 8 ◽  
Author(s):  
Hong-Liang Wang ◽  
Wei-Jie Lu ◽  
Yue-Lin Zhang ◽  
Chun-Hui Nie ◽  
Tan-Yang Zhou ◽  
...  

Aim: The purpose of our study was to conduct a retrospective analysis to compare the effectiveness of transjugular intrahepatic portosystemic shunts (TIPS) in the treatment of patients with cirrhosis with or without portal vein thrombosis (PVT).Methods: We included a total of 203 cirrhosis patients successfully treated with TIPS between January 2015 and January 2018, including 72 cirrhosis patients with PVT (35.5%) and 131 without PVT (64.5%). Our subjects were followed for at least 1 year after treatment with TIPS. Data were collected to estimate the mortality, shunt dysfunction, and complication rates after TIPS creation.Results: During the mean follow-up time of 19.5 ± 12.8 months, 21 (10.3%) patients died, 15 (7.4%) developed shunt dysfunction, and 44 (21.6%) experienced overt hepatic encephalopathy (OHE). No significant differences in mortality (P = 0.134), shunt dysfunction (P = 0.214), or OHE (P = 0.632) were noted between the groups. Age, model for end-stage liver disease (MELD) score, and refractory ascites requiring TIPS were risk factors for mortality. A history of diabetes, percutaneous transhepatic variceal embolization (PTVE), 8-mm diameter stent, and platelet (PLT) increased the risk of shunt dysfunction. The prevalence of variceal bleeding and recurrent ascites was comparable between the two groups (16.7 vs. 16.7% P = 0.998 and 2.7 vs. 3.8% P = 0.678, respectively).Conclusions: Transjugular intrahepatic portosystemic shunts are feasible in the management of cirrhosis with PVT. No significant differences in survival or shunt dysfunction were noted between the PVT and no-PVT groups. The risk of recurrent variceal bleeding, recurrent ascites, and OHE in the PVT group was generally similar to that in the no-PVT group. TIPS represents a potentially feasible treatment option in cirrhosis patients with PVT.


1988 ◽  
Vol 207 (5) ◽  
pp. 623-634 ◽  
Author(s):  
W. DEAN WARREN ◽  
J. MICHAEL HENDERSON ◽  
WILLIAM J. MILLIKAN ◽  
JOHN T. GALAMBOS ◽  
F. CURTIS BRYAN

Sign in / Sign up

Export Citation Format

Share Document